Valuation: Annexon, Inc.

Market Cap 855M 751M 699M 641M 1.2B 82.36B 1.22B 8.3B 3.24B 40.49B 3.21B 3.14B 140B P/E 2026 *
-5.55x
P/E 2027 * -6.21x
Enterprise Value 761M 668M 621M 570M 1.07B 73.26B 1.09B 7.38B 2.88B 36.02B 2.86B 2.79B 125B EV / Sales 2026 *
-
EV / Sales 2027 * 14.9x
Free-Float
93.57%
Yield 2026 *
-
Yield 2027 * -
1 day-1.51%
1 week-10.00%
Current month-8.58%
1 month+1.36%
3 months-11.22%
6 months-23.01%
Current year+3.98%
1 week 4.96
Extreme 4.96
5.92
1 month 4.96
Extreme 4.96
6.58
Current year 4.46
Extreme 4.46
7.18
1 year 2.03
Extreme 2.03
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
23.61
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 30/11/2014
Director of Finance/CFO 53 31/05/2019
Chief Tech/Sci/R&D Officer 68 26/07/2023
Director TitleAgeSince
Director/Board Member 58 30/11/2014
Director/Board Member 65 30/11/2014
Director/Board Member 67 04/02/2021
Date Insider Type Main position Quantity % Market Cap.
11/06/26 Free

Director

65,000 0.0397%
11/06/26 Free

Director

65,000 0.0397%
11/06/26 Free

Director

65,000 0.0397%
Change 5-day change 1-year change 3-year change Capi.($)
-1.51%-10.00%+107.97%+60.86% 855M
+0.93%+6.97%+59.60%+68.35% 57.28B
-1.92%+6.03%+40.64%+83.42% 54.99B
-0.46%-1.29%+2.86%+428.78% 23.18B
-2.97%-2.35%-22.53%-16.40% 22.59B
-0.36%+5.73%+24.13%-6.24% 20.46B
-1.34%+0.51%+26.03%-29.41% 17.56B
-1.44%+5.67%+38.77%+504.71% 15.67B
-1.30%-5.02%+170.77%+291.37% 14.46B
-0.50%-0.98%+21.43%+180.07% 13.92B
Average -1.09%+0.15%+46.97%+156.55% 24.1B
Weighted average by Cap. -0.87%+2.05%+39.94%+133.24%

Financials

2026 *2027 *
Net sales - 37.83M 33.22M 30.9M 28.35M 53.27M 3.64B 54.09M 367M 143M 1.79B 142M 139M 6.19B
Net income -188M -166M -154M -141M -265M -18.15B -269M -1.83B -714M -8.92B -707M -692M -30.85B -191M -168M -156M -143M -269M -18.38B -273M -1.85B -723M -9.04B -717M -701M -31.24B
Net Debt -94.47M -82.97M -77.16M -70.81M -133M -9.1B -135M -916M -358M -4.47B -355M -347M -15.46B -292M -256M -238M -219M -411M -28.11B -417M -2.83B -1.11B -13.82B -1.1B -1.07B -47.78B
Logo Annexon, Inc.
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Employees
93
Date Price Change Volume
24/07/26 US$5.220 -1.51% 2,733,766
23/07/26 US$5.300 +1.34% 2,194,269
22/07/26 US$5.230 -2.97% 1,619,854
21/07/26 US$5.390 -3.23% 2,956,278
20/07/26 US$5.570 -3.97% 2,216,349
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
5.220USD
Average target price
13.56USD
Spread / Average Target
+159.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANNX Stock